MA50752B1 - Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation - Google Patents
Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisationInfo
- Publication number
- MA50752B1 MA50752B1 MA50752A MA50752A MA50752B1 MA 50752 B1 MA50752 B1 MA 50752B1 MA 50752 A MA50752 A MA 50752A MA 50752 A MA50752 A MA 50752A MA 50752 B1 MA50752 B1 MA 50752B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- drug conjugates
- antibody drug
- activatable antibody
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572467P | 2017-10-14 | 2017-10-14 | |
| PCT/US2018/055733 WO2019075417A1 (en) | 2017-10-14 | 2018-10-12 | CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50752A MA50752A (fr) | 2020-08-12 |
| MA50752B1 true MA50752B1 (fr) | 2021-03-31 |
Family
ID=64110112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50752A MA50752B1 (fr) | 2017-10-14 | 2018-10-12 | Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation |
Country Status (36)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| PL3691692T3 (pl) * | 2017-10-14 | 2021-07-19 | Abbvie Inc. | Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania |
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CN121754667A (zh) * | 2020-04-08 | 2026-03-31 | 阿里亚达治疗公司 | 用于血脑屏障递送的组合物和方法 |
| JP2023521384A (ja) * | 2020-04-09 | 2023-05-24 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗体を含む組成物 |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CN120659627A (zh) * | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025133132A1 (en) * | 2023-12-20 | 2025-06-26 | Institut National De La Sante Et De La Recherche Medicale | Novel anti-tfr1 (cd71) antibodies for cancer treatment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| CN101888856B (zh) * | 2007-11-07 | 2014-08-27 | 塞尔德克斯医疗公司 | 结合人树突和上皮细胞205(dec-205)的抗体 |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010241706B2 (en) * | 2009-04-29 | 2015-07-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
| CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
| WO2012104344A1 (en) * | 2011-02-01 | 2012-08-09 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| PL2809683T3 (pl) * | 2012-01-31 | 2019-03-29 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| CN103145847B (zh) * | 2013-02-05 | 2014-05-21 | 浙江大学 | 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用 |
| BR112017023862A2 (pt) * | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| CN106237341B (zh) * | 2016-07-12 | 2019-07-30 | 浙江大学 | 一种抗体偶联药物及其制备方法和应用 |
| PL3691692T3 (pl) * | 2017-10-14 | 2021-07-19 | Abbvie Inc. | Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania |
-
2018
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active Active
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en not_active Withdrawn
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Ceased
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en not_active Abandoned
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh not_active IP Right Cessation
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko not_active Withdrawn
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en not_active Ceased
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko not_active Expired - Fee Related
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
-
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
-
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
-
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en not_active Abandoned
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50752B1 (fr) | Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation | |
| MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
| MA39909B1 (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
| CR20120505A (es) | Composición de fármaco conjugado | |
| WO2019014328A3 (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| MA32899B1 (fr) | Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine | |
| BR112022011032A2 (pt) | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo | |
| EP3824096A4 (en) | NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF | |
| EP3476399A4 (en) | LAG-3 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL APPLICATION THEREOF | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| MA29975B1 (fr) | Antagonistes de la neuropiline | |
| MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
| MA40041B1 (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA40671A1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| MA43345A (fr) | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation | |
| CR8317A (es) | Anticuerpos dirigidos a m-csf | |
| MA31984B1 (fr) | Formulation d'anticorps | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| ATE391174T1 (de) | Modifizierter tpo-agonisten antikörper | |
| ECSP10010056A (es) | ANTICUERPOS ANTI-IL-12/23p40, EPÍTOPES, FORMULACIONES, COMPOSICIONES, MÉTODOS Y USOS | |
| JOP20190155A1 (ar) | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم | |
| MA37407A1 (fr) | Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine | |
| EP3941946A4 (en) | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | |
| MA31793B1 (fr) | Nouveaux anticorps specifiques de peptides beta- amyloides et leurs utilisations comme agents diagnostiques ou medicaments |